Test

This is a test

Search by drug, manufacturer, or indication

Displaying 1101 - 1110 of 1165

Intuniv XR (guanfacine hydrochloride)

Status:

Negotiations were not pursued

Manufacturer:

Shire Pharma Canada ULC

Indication:

Attention-deficit/hyperactivity disorder (ADHD)

Last updated November 18, 2014

Grastek (phleum pratense)

Status:

Negotiations were not pursued

Manufacturer:

Merck Canada Inc.

Indication:

Allergy

Last updated October 30, 2014

Jetrea (ocriplasmin)

Status:

Concluded with an LOI

Manufacturer:

Alcon Canada Inc.

Indication:

Vitreomacular Adhesion

Last updated October 10, 2014

Soliris (eculizumab)

Status:

Concluded with an LOI

Manufacturer:

Alexion Pharma Canada Corp.

Indication:

Paroxysmal nocturnal hemoglobinuria (PNH)

Last updated October 5, 2014

Aubagio (teriflunomide)

Status:

Concluded with an LOI

Manufacturer:

Sanofi Genzyme Canada

Indication:

Multiple Sclerosis, Relapsing

Last updated September 26, 2014

Zaltrap (aflibercept)

Status:

Negotiations were not pursued

Manufacturer:

Regeneron

Indication:

Metastatic Colorectal Cancer

Last updated September 25, 2014

Orencia (abatacept)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Rheumatoid Arthritis

Last updated September 10, 2014

Galexos (simeprevir)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Chronic Hepatitis C

Last updated August 20, 2014

Esbriet (pirfenidone)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Pulmonary fibrosis (idiopathic, mild to moderate)

Last updated August 15, 2014

Stivarga (regorafenib)

Status:

Concluded with an LOI

Manufacturer:

Bayer Inc.

Indication:

Gastrointestinal Stromal Tumours

Last updated August 11, 2014